Novo Nordisk’s Wegovy sales jump on international rollouts
Novo’s obesity drug sales nearly doubled outside the U.S. during the quarter as global demand continued to rise.
Yen.com.gh19m
Obesity drug maker Novo Nordisk posts strong profit
Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted ...
Novo Nordisk posts Q3 sales of obesity drug Wegovy above expected forecast
Novo Nordisk on Wednesday reported better-than-expected quarterly sales of its popular Wegovy weight-loss drug and narrowed ...
Novo Nordisk’s Wegovy Sales Surge on Crucial US Market
Novo Nordisk A/S’s sales of the blockbuster weight-loss drug Wegovy leapt in the third quarter, a potential relief for ...
pharmaphorum1h
Wegovy romps ahead after key rival sees slowdown
GLP-1 agonist Wegovy (semaglutide) brought in DKK 17.3 billion ($2.49 billion) in the period, restoring earlier levels of ...
STAT1h
Novo’s earnings report sends shares up, as obesity drug sales show continued growth
Novo Nordisk shares were up Wednesday following an earnings report that showed continued sales growth of its obesity drug.
Novo Nordisk's Blockbuster Wegovy Sales Beat Expectations — Update
Novo Nordisk's net profit in the third quarter rose 21% to 27.3 billion kroner, ahead of the 26.79 billion kroner forecast by analysts in a FactSet poll. Sales rose 21% to 71.31 billion kroner, ...
NBC Los Angeles3h
Novo Nordisk quarterly profit meets expectations as Wegovy maker narrows full-year guidance
Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year ...
Novo Nordisk’s Blockbuster Wegovy Sales Beat Expectations
The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.
Novo Nordisk narrows 2024 guidance range, Q3 in line with expectations
Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations ...